INSERM U970, Paris Cardiovascular Research Center, Paris, France.
Eur Respir J. 2013 Jul;42(1):272-9. doi: 10.1183/09031936.00087212. Epub 2012 Dec 20.
Pulmonary hypertension (PH) is a fatal disease with no treatment options, characterised by elevated pulmonary vascular resistanzce and secondary right ventricular failure. The aetiology of pulmonary arterial hypertension is multiple and its pathogenesis is complex. Although the exact role of cellular microparticles remains partially understood, there is increasing evidence to suggest an active role for microparticles in PH pathophysiology. Patients with PH exhibited higher circulating levels of microparticles compared to control subjects and in vitro or in vivo generated microparticles can induce endothelial dysfunction, interfere with coagulation pathways or modulate inflammatory phenomenon. Whether or not these new conveyors of biological information contribute to the acquisition and/or maintenance of the altered endothelial phenotype is unexplored in PH and requires further study.
肺动脉高压(PH)是一种致命的疾病,目前尚无治疗方法,其特征为肺血管阻力升高和继发性右心衰竭。肺动脉高压的病因有多种,发病机制复杂。尽管细胞微颗粒的确切作用部分尚不清楚,但越来越多的证据表明微颗粒在 PH 病理生理学中发挥着积极作用。与对照组相比,PH 患者的循环中存在更高水平的微颗粒,体外或体内产生的微颗粒可诱导内皮功能障碍、干扰凝血途径或调节炎症现象。这些新的生物信息载体是否有助于获得和/或维持改变的内皮表型在 PH 中尚未得到探索,需要进一步研究。